Navigation Links
Biomarker identified in relation to drug response in refractory urothelial cancer
Date:3/31/2012

CHICAGO The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.

"Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea Necchi, M.D., faculty member in the department of medicine at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. "Patients who fail to be cured after multiple chemotherapy regimens have a poor survival estimate, and palliative care is a reasonable trade-off."

Data from the phase II proof-of-concept trial identified pazopanib as the first targeted compound to have clinically meaningful activity in patients with refractory urothelial cancer, according to Necchi.

"Our data indicate that pazopanib seems to be a legitimate drug in this disease," said Necchi. "Most interestingly, our biomarker analysis clearly pointed out the role of rising levels of circulating interleukin-8 as an early and potentially practice-changing indicator of tumor resistance and poor survival."

The researchers assigned 41 patients with relapsing or progressing urothelial cancer between 2010 and 2011 to 800 mg once-daily pazopanib. All patients had at least one prior chemotherapy regimen for metastatic disease.

At follow-up, seven patients had a partial response to therapy and 24 patients had stable disease an overall clinical benefit of 76 percent. Median progression-free survival was 2.6 months, and median overall survival was 4.7 months. However, 10 percent of patients had a long-term cure after a median follow-up of 19 months.

The researchers examined blood samples for predictive biomarkers at baseline and every four weeks. They found that early rising levels of interleukin-8 (e.g., after four weeks of pazopanib) were associated with tumor progression and shorter overall survival.

"This trial gave a clear proof of concept that will require confirmation on a larger number of patients," Necchi said. "However, the preliminary findings, mainly regarding the role of interleukin-8 levels, have the potential to change at least the concept of new trial design with antiangiogenic agents in this disease."

Necchi served as an adviser and consultant for GlaxoSmithKline Inc. The current study was sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori. GlaxoSmithKline Inc. provided the drug supply and granted independent radiologic review, which was performed at Columbia University Medical Center.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Panel of serum biomarkers may reduce number of lung biopsies needed
2. Biomarkers identify acute kidney injury in emergency patients
3. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
4. Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
5. Mass. General Cancer Center and Vall dHebron Institute of Oncology biomarker alliance
6. Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease
7. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
8. Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio
9. FDA clears biomarker test for ovarian cancer
10. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
11. Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology: